Halia Therapeutics, a clinical-stage biopharmaceutical company advancing medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, has opened its new 20,000 sq.-ft. headquarters in Lehi, UT.
 
The new building will house a variety of state-of-the-art research and development lab equipment managed by 18 current, full-time employees and contractors. The facility is dedicated to the development of novel therapies for patients with inflammatory and neurological diseases. It aims to provide flexibility, integration, and the ability to streamline drug discovery processes and to promote collaboration within the company and affiliates.
 
The HQ will also promote precise environmental control in scientific research with individually temperature-controlled rooms to ensure the highest quality of research while supporting sustainability.